The University of Southampton
University of Southampton Institutional Repository

Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors

Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors
Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors
This study aimed to assess the clinical impact of 68Ga-DOTATATE and 18F-FDG with respect to the management plan and to evaluate the prognostic value of both tracers.

Methods: a total of 104 patients (55 male and 49 female; median age, 58 y; range, 20-90 y) with histologically proven neuroendocrine tumors (NETs) underwent both 68Ga-DOTATATE and 18F-FDG PET/CT. Twenty-eight patients (26.9%) had poorly differentiated tumors, and 76 (73.1%) had well differentiated tumors. PET/CT results and SUVs were compared with prognostic factors such as histologic grade (G1, G2, or G3, for low-grade [well differentiated], intermediate-grade [moderately differentiated], and high-grade [poorly differentiated], respectively), chromogranin A, and proliferation index (Ki-67).

Results: the 68Ga-DOTATATE and 18F-FDG PET/CT findings were discordant in 65 patients (62.5%) and concordant in 39 patients (37.5%). The results changed the therapeutic plan in 84 patients (80.8%). In 22 patients (21.1%), decision making was based on the 18F-FDG findings; in 32 (30.8%), on the findings with both radiotracers; and in 50 (48.1%), on the 68Ga-DOTATATE findings. The most frequent management decision based on 18F-FDG was initiation of chemotherapy (10 patients, 47.6%). The most common treatment decision due to 68Ga-DOTATATE was initiation of peptide receptor radionuclide therapy (14 patients, 27.4%). In 11 (39.2%) of 28 patients with poorly differentiated NETs, the management decision was based on only the 18F-FDG results. For 68Ga-DOTATATE, SUVmax was higher for G1 tumors and lower for G3 tumors (P 5 0.012). However, no significant differences in 18F-FDGderived SUVs were observed between different grades (P 5 0.38). The Mann-Whitney test showed significant differences in 68Ga-DOTATATE SUVmax between tumors with a Ki-67 of less than 5% and tumors with a Ki-67 of more than 5% (P 5 0.004), without significance differences in 18F-FDG SUVmax. Log-rank analysis showed statistically significant differences in survival for patients with bone metastasis versus soft-Tissue or no metastasis for both 18F-FDG (P 5 0.037) and 68Ga-DOTATATE (P 5 0.047). Overall survival declined rapidly with increasing grade (P 5 0.001), at an estimated 91 mo for G1, 59 mo for G2, and 48 mo for G3.

Conclusion: 18F-FDG PET/CT had no clinical impact on G1 NETs and a moderate impact on G2 NETs. However, in poorly differentiated NETs, 18F-FDG PET/CT plays a significant clinical role in combination with 68Ga-DOTATATE. 68Ga DOTATATE SUVmax relates to grade and Ki-67 and can be used prognostically. Key Words: 68Ga-DOTATATE; 18F-FDG PET/CT; neuroendocrine tumors; clinical impact; prognosis.
2159-662X
91-96
Panagiotidis, Emmanouil
9d13d090-665b-4660-b8f1-b611cc1f4857
Alshammari, Alshaima
cd7dc945-9ade-4aa0-8305-64ea1d2ee21d
Michopoulou, Sofia
f21ba2a3-f5d3-4998-801f-1ae72ff5d92c
Skoura, Evangelia
646470ea-a102-4969-b3b7-14115055fe5b
Naik, Keval
7a3b09c1-428e-4cda-8033-fdc2e38294cf
Maragkoudakis, Emmanouil
1f53672b-0921-4877-bd0d-1742de9a723f
Mohmaduvesh, Mullan
0fc51c44-e59c-4d48-84b7-c2557048b9d9
Al-Harbi, Mohammed
bd94c1e2-eae3-49a5-ab1f-f9efe90f7420
Belda, Maria
658c836f-8bd6-46d5-a050-af18189a16f5
Caplin, Martyn E.
b00b4bdb-ebb1-45d9-9cd7-054c00ad2d4c
Toumpanakis, Christos
015476d1-fc90-4dae-ade9-20fc04ceff82
Bomanji, Jamshed
a0c39034-3f30-4ceb-8360-c22126aafa6b
Panagiotidis, Emmanouil
9d13d090-665b-4660-b8f1-b611cc1f4857
Alshammari, Alshaima
cd7dc945-9ade-4aa0-8305-64ea1d2ee21d
Michopoulou, Sofia
f21ba2a3-f5d3-4998-801f-1ae72ff5d92c
Skoura, Evangelia
646470ea-a102-4969-b3b7-14115055fe5b
Naik, Keval
7a3b09c1-428e-4cda-8033-fdc2e38294cf
Maragkoudakis, Emmanouil
1f53672b-0921-4877-bd0d-1742de9a723f
Mohmaduvesh, Mullan
0fc51c44-e59c-4d48-84b7-c2557048b9d9
Al-Harbi, Mohammed
bd94c1e2-eae3-49a5-ab1f-f9efe90f7420
Belda, Maria
658c836f-8bd6-46d5-a050-af18189a16f5
Caplin, Martyn E.
b00b4bdb-ebb1-45d9-9cd7-054c00ad2d4c
Toumpanakis, Christos
015476d1-fc90-4dae-ade9-20fc04ceff82
Bomanji, Jamshed
a0c39034-3f30-4ceb-8360-c22126aafa6b

Panagiotidis, Emmanouil, Alshammari, Alshaima, Michopoulou, Sofia, Skoura, Evangelia, Naik, Keval, Maragkoudakis, Emmanouil, Mohmaduvesh, Mullan, Al-Harbi, Mohammed, Belda, Maria, Caplin, Martyn E., Toumpanakis, Christos and Bomanji, Jamshed (2017) Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. Journal of Nuclear Medicine, 58 (1), 91-96. (doi:10.2967/jnumed.116.178095).

Record type: Article

Abstract

This study aimed to assess the clinical impact of 68Ga-DOTATATE and 18F-FDG with respect to the management plan and to evaluate the prognostic value of both tracers.

Methods: a total of 104 patients (55 male and 49 female; median age, 58 y; range, 20-90 y) with histologically proven neuroendocrine tumors (NETs) underwent both 68Ga-DOTATATE and 18F-FDG PET/CT. Twenty-eight patients (26.9%) had poorly differentiated tumors, and 76 (73.1%) had well differentiated tumors. PET/CT results and SUVs were compared with prognostic factors such as histologic grade (G1, G2, or G3, for low-grade [well differentiated], intermediate-grade [moderately differentiated], and high-grade [poorly differentiated], respectively), chromogranin A, and proliferation index (Ki-67).

Results: the 68Ga-DOTATATE and 18F-FDG PET/CT findings were discordant in 65 patients (62.5%) and concordant in 39 patients (37.5%). The results changed the therapeutic plan in 84 patients (80.8%). In 22 patients (21.1%), decision making was based on the 18F-FDG findings; in 32 (30.8%), on the findings with both radiotracers; and in 50 (48.1%), on the 68Ga-DOTATATE findings. The most frequent management decision based on 18F-FDG was initiation of chemotherapy (10 patients, 47.6%). The most common treatment decision due to 68Ga-DOTATATE was initiation of peptide receptor radionuclide therapy (14 patients, 27.4%). In 11 (39.2%) of 28 patients with poorly differentiated NETs, the management decision was based on only the 18F-FDG results. For 68Ga-DOTATATE, SUVmax was higher for G1 tumors and lower for G3 tumors (P 5 0.012). However, no significant differences in 18F-FDGderived SUVs were observed between different grades (P 5 0.38). The Mann-Whitney test showed significant differences in 68Ga-DOTATATE SUVmax between tumors with a Ki-67 of less than 5% and tumors with a Ki-67 of more than 5% (P 5 0.004), without significance differences in 18F-FDG SUVmax. Log-rank analysis showed statistically significant differences in survival for patients with bone metastasis versus soft-Tissue or no metastasis for both 18F-FDG (P 5 0.037) and 68Ga-DOTATATE (P 5 0.047). Overall survival declined rapidly with increasing grade (P 5 0.001), at an estimated 91 mo for G1, 59 mo for G2, and 48 mo for G3.

Conclusion: 18F-FDG PET/CT had no clinical impact on G1 NETs and a moderate impact on G2 NETs. However, in poorly differentiated NETs, 18F-FDG PET/CT plays a significant clinical role in combination with 68Ga-DOTATATE. 68Ga DOTATATE SUVmax relates to grade and Ki-67 and can be used prognostically. Key Words: 68Ga-DOTATATE; 18F-FDG PET/CT; neuroendocrine tumors; clinical impact; prognosis.

Text
91.full - Version of Record
Available under License Creative Commons Attribution.
Download (237kB)

More information

Accepted/In Press date: 30 June 2016
e-pub ahead of print date: 3 January 2017

Identifiers

Local EPrints ID: 487902
URI: http://eprints.soton.ac.uk/id/eprint/487902
ISSN: 2159-662X
PURE UUID: 9f866166-b6d1-4295-b46f-b8d0db5d1d7e

Catalogue record

Date deposited: 08 Mar 2024 18:00
Last modified: 30 May 2024 17:16

Export record

Altmetrics

Contributors

Author: Emmanouil Panagiotidis
Author: Alshaima Alshammari
Author: Sofia Michopoulou
Author: Evangelia Skoura
Author: Keval Naik
Author: Emmanouil Maragkoudakis
Author: Mullan Mohmaduvesh
Author: Mohammed Al-Harbi
Author: Maria Belda
Author: Martyn E. Caplin
Author: Christos Toumpanakis
Author: Jamshed Bomanji

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×